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A B S T R A C T   
Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological 
conditions including the fatal neuromuscular disease Duchenne Muscular Dystrophy (DMD). DMD is a compli-
cated disease, with many druggable targets at the cellular and molecular level including calcium-mediated 
muscle degeneration; mitochondrial dysfunction; oxidative stress; inflammation; insufficient muscle regenera-
tion and dysregulated protein and organelle maintenance. Previous investigative therapeutics tended to isolate 
and focus on just one of these targets and, consequently, therapeutic activity has been limited. Nuclear erythroid 
2-related factor 2 (Nrf2) is a transcription factor that upregulates many cytoprotective gene products in response 
to oxidants and other toxic stressors. Unlike other strategies, targeted Nrf2 activation has the potential to 
simultaneously modulate separate pathological features of DMD to amplify therapeutic benefits. Here, we review 
the literature providing theoretical context for targeting Nrf2 as a disease modifying treatment against DMD.   
1. Introduction 
Reactive oxygen species (ROS) form under normal physiological 
conditions due to the partial reduction of molecular oxygen (O2) [1] 
and, despite being harmful by nature, they are fundamentally important 
for many physiological processes as functional signalling entities [2]. 
Moderate levels of ROS are continuously produced by skeletal muscles 
due to their contractile activity and high O2 consumption by the mito-
chondria. Muscle ROS production is amplified during times of metabolic 
stress when adenosine triphosphate (ATP) demand is high, such as 
during exercise, and are buffered by multiple antioxidant systems to 
maintain redox homeostasis [3]. Redox imbalance, when ROS produc-
tion exceeds the physiological buffering capacity, results in oxidative 
stress [4], which is implicated in many pathological conditions 
including the fatal skeletal muscle wasting disease, Duchenne Muscular 
Dystrophy (DMD). 
DMD is a rare, progressive neuromuscular disorder arising from 
frame-shift mutations in the dystrophin gene [5]. The mutations, and 
consequential missing protein, compromise stability and integrity of the 
skeletal muscle membrane causing the progression of muscle damage, 
inflammation, degeneration, and wasting [6]. Death occurs typically 
within the third decade of life due to cardiorespiratory failure [5,7]. 
Currently, there is no cure and standard of care corticosteroid therapy 
only slows the progression of the disease [8], and often imparts severe 
side effects making it unsuitable for the treatment of some patients [8,9]. 
Emerging genome editing technologies such as CRISPR-Cas9 [10] and 
TALEN [10] systems offer a new avenue for a potential cure of DMD. 
Although technical challenges such as efficacy, delivery and accuracy of 
the genome editing components remain to be improved, exon skipping 
in particular has positively progressed under accelerated approval based 
upon limited dystrophin expression [11–15]. However, a clinical benefit 
is not yet established and escalating side-effect profiles have been 
identified through post-approval surveillance. Thus, a high unmet clin-
ical need remains for new effective therapeutics with favourable side 
effect profiles that can be rapidly translated into clinical utility. 
DMD is a pathophysiologically complex disease with many drug-
gable targets including calcium (Ca2+) regulation [16], mitochondria [3, 
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17–19], antioxidant defence systems [3,20,21], inflammatory and im-
mune responses [7,21–23], satellite cell cycling-mediated regeneration 
[24–26] as well as protein maintenance regulators [27–29]. Experi-
mental therapeutics in the past have mostly focused on just one of these 
targets and as such, the therapeutic benefit of these approaches has been 
limited. A superior therapeutic strategy would be to simultaneously 
modulate each of these targets to amplify remedial potential. Upon 
activation, one pathway with the capacity to do this is the nuclear factor 
erythroid 2-related factor 2 (Nrf2) signalling pathway, which is both a 
canonical and non-canonical inducer of the cytoprotective response that 
protects cells from oxidative and other stressors [30]. Nrf2 affects key 
molecular responses, which address the numerous molecular mediators 
of dystropathology. Currently, several pharmaceutical and nutraceutical 
activators of Nrf2 are at different stages of clinical development for the 
treatment of diseases associated with oxidative stress. However, the only 
potent, safe and well-characterised pharmacological activators of Nrf2 
currently approved for human use are the fumaric acid esters: mono-
methylfumarate (MMF), dimethyl fumarate (DMF) and the MMF 
pro-drug formulation, diroximel fumarate (DRF), for Multiple Sclerosis 
(MS) indication; oltipraz, for schistosomiasis indication; and ursodiol, 
for primary biliary cirrhosis indication. This review will explore the 
literature establishing a theoretical context for targeted Nrf2 therapy to 
treat DMD with the view toward future confirmatory clinical trials. 
2. ROS and skeletal muscle: Friend or foe? 
Skeletal muscles contribute to essential bodily functions including 
movement, respiration, metabolism and hormonal regulation [26]. 
Effective muscle function is both energetically and mechanically 
demanding making it highly susceptible to damage, which, if extensive 
and chronic, can limit mobility and contribute to metabolic disease. 
Thus, successful maintenance of muscle function throughout life rep-
resents an imperative and critical challenge to healthcare. 
Highly metabolic tissues like skeletal muscle are a constant source of 
ROS and reactive nitrogen species (RNS) [1]. ROS/RNS can be produced 
in numerous cellular compartments such as the endoplasmic reticulum, 
lysosomes, peroxisomes and most commonly, the cytosol and mito-
chondria [31,32]. The main source of ROS production occurs in the 
cytosol through the activity of nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidases (NOX enzymes), xanthine oxidase (XO) and 
nitric oxide synthase (NOS) [32,33], and by the mitochondrial electron 
transport chain (ETC) [32,33]. Since oxidative damage to biomolecules 
can have detrimental effects on homeostasis and cellular physiology, 
oxidative stress is suggested to play a critical role in primary myopathies 
as well as other diseases which notably feature skeletal muscle dysfunc-
tion and/or wasting, including: mitochondrial diseases [34], age-related 
disorders [35] and neurodegenerative diseases [36–38]. Paradoxically, 
skeletal muscle also relies on ROS/RNS as important signalling molecules 
to internally regulate cellular function relative to environmental de-
mands. Physical activity, as well as caloric restriction, transiently in-
creases mitochondrial ROS production to induce mitohormesis [39,40]. 
In this process low, temporal concentrations of mitochondrial ROS act as 
signalling molecules to initiate a cascade of cellular events that ulti-
mately protect against harmful events [40,41]. For example, during ex-
ercise, ROS promotes mitochondrial biogenesis via the peroxisome 
proliferator-activated-receptor-gamma-coactivator-1α (PGC-1α) signal-
ling pathway [42] to facilitate increased ATP production capacity that is 
required during exercise. However, chronic exposure to ROS paired with 
inadequate buffering capacity, damages muscle [1] and impairs its 
regeneration [43]. The type of response, and whether it is beneficial or 
detrimental, depends on numerous variables such as the origin and 
reactivity of ROS, the tenacity of ROS generation and the cellular 
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antioxidant status [1]. Endogenous antioxidant systems have evolved to 
mitigate many forms of oxidative/nitrosative stress and are themselves 
regulated by mitohormesis. 
2.1. Hormesis: Beneficial adaptations by ROS 
Hormesis refers to a process where exposure to a low toxic insult 
(that would otherwise be damaging at higher doses), induces a benefi-
cial, adaptive effect that is integral to the physiological function of cells 
and organisms [44]. Hormesis is a foundational concept in evolutionary 
theory where, to avoid harm, organisms have developed intricate mo-
lecular mechanisms to survive stress. As an example, an acute bout of 
heavy exercise generates enough ROS to potentially hinder muscle en-
ergy production and contractile function in the short-term [45], but, is 
essential for increasing the resistance of musculoskeletal and cardio-
vascular systems to injury and disease in the long-term [46]. Thus, 
hormesis promotes the beneficial cellular adaptations of exercise, which 
could otherwise be considered a toxic insult. 
The main classes of hormetic stress resistance proteins that are 
conserved across tissues and species have been identified and include, 
but are not limited to, antioxidant enzymes [47] and protein chaperones 
[48]. Upregulation of the endogenous antioxidant system is the funda-
mental response to ROS-induced stress and is aimed at quenching su-
perfluous ROS before they can cause harm to tissues. Antioxidant 
enzymes are involved in the catalytic transformation of ROS and their 
by-products into stable, non-toxic molecules thus representing critical 
defence mechanisms against oxidative damage [49]. The endogenous 
antioxidant defence system includes enzymes such as superoxide dis-
mutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and per-
oxiredoxins (PRDX), and the tripeptide glutathione (GSH). These 
antioxidants are abundant in oxidative (Type I and IIa/x) muscle fibres 
[50–52] and their deficiency, i.e. SOD1 [50,51], is indicative of oxida-
tive stress. A secondary endogenous antioxidant defence system also 
exists in the inducible Phase II enzymes – these are activated by a 
plethora of stimuli such as xenobiotics and drugs [53], endogenous in-
ducers including ROS, lipid peroxidation products and RNS [54], and 
chemical compounds including isothiocyanates and phenols [55]. Heme 
oxygenase-1 (HO-1) is responsible for the synthesis of non-enzymatic 
antioxidants present in skeletal muscle (biliverdin and bilirubin) and 
has been suggested to play an important role in the regulatory mecha-
nism of heme catabolism in skeletal muscle tissue [50]. Nicotinamide 
adenine dinucleotide phosphate quinone oxidoreductase 1 (NQO1) is 
highly inducible and plays crucial roles in cellular adaptation to stress 
[51], acts as a direct superoxide anion (O2• − ) reductase [52] and is 
significantly elevated in skeletal muscles in response to aerobic exercise 
[52]. Balance between production of ROS and antioxidant enzyme 
expression and activity plays an important role to maintain redox ho-
meostasis, while an imbalance has been proposed to progress and 
exacerbate several muscle-related pathologies such as DMD. 
Rather than flicking a molecular on/off switch, hormesis drives 
biological plasticity according to a graded dose response (either a J- 
shaped or an inverted U-shaped curve) and through the integration of 
multiple molecular signals and pathways. In this regard and consistent 
with most dose-response curves, there is a “ceiling response” which 
defines the capacity of hormesis to resist any one molecular stress signal. 
However, the “ceiling” is highly influenced by the local environment 
and thus may vary substantially between healthy and disease states 
resulting in insufficient hormesis, failure of redox homeostasis and 
accelerated pathogenesis [56]. This is particularly true for chronic dis-
eases like DMD, which are underscored by a permanent harmful chal-
lenge (e.g. driven by the lack of dystrophin) and an inappropriate 
response to injury (e.g. driven by a hyper-inflammatory and pro-fibrotic 
response), which critically challenges hormesis. Importantly, there is 
evidence to suggest that hormesis remains amenable to rheostatic 
manipulation even once the theoretical “ceiling” has been reached, and 
this is because hormetic pathways integrate many signals from multiple 
molecular pathways through canonical, non-canonical and comple-
mentary positive and negative feed-back loops. These avenues can be 
exploited in disease states to re-establish hormetic control: for Nrf2, this 
is exemplified through the successful application of DMF in the treat-
ment of the dysregulated immuno- and inflammatory responses associ-
ated with MS. But can hormesis by overdone? There is burgeoning 
evidence to suggest that persistent unsolicited Nrf2 overactivation, 
particularly alongside dysregulated autophagy, can progress cardiac 
disease despite being initially beneficial for resisting myocardial damage 
[57]. Thus, a molecular “tipping-point” clearly exists, which is depen-
dent upon the pathological environment and the proper function and/or 
amenability to modulation of the downstream cytoprotective events that 
are governed by Nrf2 (i.e. autophagy). This is important to consider in 
the context of drug-targeting Nrf2 against chronic disease given the 
longevity of the treatment needed. 
3. Duchenne Muscular Dystrophy: When ROS become foes 
Progressive muscle wasting conditions like the fatal DMD are 
underscored by chronic ROS production, which exceeds hormetic ca-
pacity. Under these conditions, muscle damage, inflammation and 
degradation drives disease progression. Designated a rare disease, DMD 
affects 1 in 3500–7000 live male births worldwide [58,59] and is a 
X-linked recessive disorder arising from mutations in the dystrophin 
(Dys) gene [60], the largest gene in the human genome [5]. Dys muta-
tions result in the ablation of dystrophin, an integral structural cyto-
skeletal protein that stabilises skeletal and cardiac muscle membranes 
[23,61]. In healthy muscles, the amino-terminus of dystrophin binds to 
F-actin with the carboxyl terminus binding to the dystrophin-associated 
protein complex (DAPC) at the sarcolemma [5]. In the absence of dys-
trophin, the DAPC is destabilized rendering muscle fibres susceptible to 
stretch-induced damage [5] and elevated intracellular Ca2+ influx [62] 
leading to a series of pathological processes that are responsible for 
skeletal and cardiac muscle damage, chronic inflammation [5] and ne-
crosis [63]. The hyper-inflammatory environment drives the deposition 
of non-functional lipid and fibrous tissue resulting in progressive muscle 
weakness [64]. Dystrophic symptomology, such as muscular weakness 
and exercise intolerance [65], is observed between the ages of 2 and 5 
with loss of ambulation occurring by early adolescence [59]. Thereafter, 
patients are wheelchair-bound and comorbidities such as scoliosis and 
muscular contractures rapidly progress [6]. Even with medical care, 
DMD patients ultimately die from cardiac and/or respiratory failure 
within the third decade of life [59,61]. There is currently no cure for 
DMD and its symptomology is treated non-specifically with corticoste-
roids (prednisone or deflazacort) as standard of care, despite them 
eliciting often serious side effects, which limit clinical utility [66,67]. 
DMD pathogenesis is multifaceted and only partially understood. We 
and others have documented mitochondrial dysfunction [19,62,68,69] 
and oxidative stress [17,19,70–72] as central features of the disease. 
Specifically, we discovered that a mitochondrial Complex I deficit was 
implicit in the cascade leading to energy depletion, which could be 
partially recovered by re-routing metabolic flux through Complex II 
(and chemically inhibiting Complex I) [62]. Others have reported 
similar mitochondrial aberrations [20,73,74] culminating in energy 
production deficits [62,73], which may influence the capacity of the 
muscle to mitigate damage and initiate repair since these processes are 
energetically-expensive. Furthermore, dysfunctional dystrophic mito-
chondria generate toxic amounts of ROS [17,19,62,68,69,75] resulting 
in protein and lipid damage via elevated 4-hydroxynonenal (4-HNE) 
[76], peroxynitrite [75], and oxidative [17] and nitrosative stress [75], 
all of which drive the dystrophic condition. Despite dystrophic muscle – 
from human patients and the genetically homologous mdx mouse model 
– expressing higher levels of antioxidants including SOD and CAT during 
peak muscle damage periods [77–79], overall antioxidant capacity ap-
pears to be insufficient to mitigate ROS as evidenced by lipid [80] and 
protein [81] peroxidation and hypersecretion of pro-inflammatory 
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cytokines [22,82]. Antioxidant treatment of dystrophic mdx mice 
showed demonstrable benefits in maintaining contractile function and 
muscle mass [83–91] whilst reducing oxidative damage and inflam-
mation [83–90,92,93] (as summarised in Table 1). As well as having 
direct ROS-scavenging activity, most of these compounds have also been 
shown to activate Nrf2 to some degree [94] suggesting that their ther-
apeutic potential depends upon pro-oxidant activity or other co-factors 
which drive Nrf2-dependent hormesis. 
Nrf2 is the primary regulator of the endogenous antioxidant response 
and several Nrf2 activators, or molecules that specifically activate Nrf2- 
dependent signalling, have been identified/developed. Direct Nrf2 
activation may provide a more efficient alternative to indirect modula-
tion through pro-oxidant production to ensure that the magnitude and 
durability of the endogenous antioxidant response is enough to sustain 
hormesis and produce a durable benefit in chronic disease states. This is 
particularly true for the clinically-established Nrf2 activator drugs (e.g. 
the fumaric acid esters, oltipraz and ursodiol) since many “natural” 
compounds with antioxidative activity have poor bioavailability and 
therefore limited translational efficacy (as has been purported for cur-
cumin [95] and the polyphenols [96]). Hence pharmacological induc-
tion of the endogenous antioxidant response of Nrf2 will be the forward 
focus of this review. 
4. Targeting Nrf2 and its downstream effectors 
The Nrf2 signalling pathway has been associated with the regulation 
of over 600 target genes [103], 200 of which are recognised to encode 
cytoprotective proteins [104] and endogenous and exogenous stress 
responses caused by ROS and electrophiles [105]. The core signalling 
proteins involved in this pathway are the transcription factor Nrf2, 
which binds to the antioxidant response element (ARE) in the regulatory 
regions of target genes [106] and Kelch-like ECH-associated protein 1 
(Keap1), a Nrf2 repressor, that promotes Nrf2 degradation via the 
ubiquitin proteasome pathway [106]. Keap1 is rich in cysteine residues 
that attaches to cytosolic actin and associates with cullin-3 protein 
(Cul3) to form the Cul3-based E3 ubiquitin ligase complex, which tar-
gets substrates for ubiquitin-dependent degradation by the 26S protea-
some [107]. Under normal conditions, Nrf2 is bound to two Keap1 
molecules [106] and is ubiquitinated by the Cul3-based E3 ubiquitin 
ligase complex resulting in rapid degradation of constitutively syn-
thesised Nrf2 via the proteasome [105,108]. However, a small amount 
of Nrf2 avoids this complex allowing for translocation of the transcrip-
tion factor to the nucleus in order to mediate basal ARE-dependant gene 
expression [106]. Under stress conditions, canonical Nrf2 inducers, 
including ROS, electrophiles, toxins and pharmacological agents, alter 
the cysteines on Keap1, which inhibits Nrf2 degradation in one of two 
ways. In the first instance, modification of specific Keap1 cysteine res-
idues leads to conformational changes and partial detachment of Nrf2 
from Keap1, thus disrupting ubiquitination and degradation of Nrf2109. 
Alternatively, complete disruption of Keap1 and Cul3 interaction in 
response to electrophiles allow Nrf2 to escape proteasomal degradation 
[106,109]. In both of these models, Keap1 and its repressor activity, is 
quenched allowing newly synthesised Nrf2 proteins and stabilizer pro-
tein deglycase (DJ-1/PARK7) to translocate into the nucleus where it 
can bind to the ARE and drive the expression of antioxidant enzymes 
[105,110] (Fig. 1). Additionally, a number of mechanisms where the 
Nrf2 pathway is non-canonically activated have also been described: (1) 
hypermethylation of Keap1, which reduces Keap1 mRNA expression and 
causes accumulation of Nrf2 in the nucleus [111,112]; (2) loss of 
fumarate hydratase enzyme activity (catalyses reversible hydration of 
fumarate to malate [113]), or alternatively, supplemental fumarate, 
which induces fumarate-dependent succination of Keap1, disrupts 
Nrf2/Keap1 binding and results in accumulation of Nrf2 [114]; and (3) 
accumulation of disruptor proteins p21 (directly interacts with motifs on 
Nrf2 competing for binding with Keap1 [115]) and p62 (directly binds 
to Keap1 inhibiting Nrf2 interaction and promoting autophagic degra-
dation of Keap1 [115]), which lead to nuclear translocation of Nrf2. 
Importantly, Nrf2 also induces p62 expression, resulting in the sustained 
activation of Nrf2 via a positive feedback loop [29]. Nrf2 regulates the 
transcription of enzymes involved in Phase II detoxification of exoge-
nous and endogenous products (ROS and xenobiotics) and heme meta-
bolism, playing a pivotal role in maintaining redox homeostasis in the 
cell. As well as these responses, Nrf2 is also involved in other cellular 
processes including Ca2+ regulation, inflammation, intermediary 
metabolism, autophagy, protein folding responses and stem cell quies-
cence (as summarised in Fig. 1). The many modes of regulation of Nrf2 
activity and the current understanding of Nrf2-mediated transcriptional 
control will be outlined hereafter. 
Table 1 
Antioxidant treatments with pre-clinical efficacy in the mdx mouse model of DMD.  
Class Compound Dosage Summary of effects 
Direct Nrf2 Activator Curcumin 0.1, 0.5 or 1 mg/kg daily for 
10 days 
Improved sarcolemmal integrity, muscle strength and histopathological features; 
decreased inflammation with all doses - effects most apparent at 1 mg/kg87 
Sulforaphane 2 mg/kg daily for 8 weeks Increased muscle mass and function and expression of Phase II enzymes [97] 
2 mg/kg daily for 4 weeks Decreased inflammation and increased HO-1 expression [98] 
2 mg/kg daily for 3 months Reduced inflammation and skeletal and cardiac muscle fibrosis [99] 
Antioxidant (with possible 
hormetic Nrf2 activation) 
Adenylosuccinic acid 
(ASA) 
300 mg/mL in drinking 
water for 8 weeks 
Improved histopathological features and mitochondrial pool viability; reduced 
mitochondrial ROS [19] 
Idebenone 200 mg/kg via oral gavage 
for 9 months 
Reduced cardiac inflammation and fibrosis, increased cardiac function, prevented 
dobutamine-induced cardiac mortality, increased voluntary wheel-running [100] 
Melatonin 30 mg/kg daily for 11 days Improved muscle function and muscle redox status [89] 
N-acetylcysteine 2% in drinking water for 6 
weeks 
Reduced oxidative stress and inflammation and improved overall muscle function 
[84–86] 
1% in drinking water for 14 
days 
Improved contractile muscle function and reduced infiltration of collagen and 
inflammatory cells [90] 
Resveratrol 4 g/kg in food daily for 32 
weeks 
Decreased ROS and oxidative damage with increased muscle mass [88] 
100 mg/kg every second day 
for 8 weeks 
Improved muscle function but had no effect on oxidative capacity despite slight 
improvements in muscle pathology [91] 
0.4 g/kg in food daily for 56 
weeks 
Ameliorated cardiomyopathy with significant reductions in ROS levels [93] 
Taurine 16 g/kg daily in drinking 
water for 6 weeks 
Decreased inflammation and protein oxidation [92] 
Vitamin C 200 mg/kg daily via oral 
gavage daily for 14 days 
Reduced muscle fibre damage, oxidative stress and inflammation [101] 
Vitamin E 40 mg/kg via oral gavage 
daily for 14 days 
Reduced muscle fibre damage, oxidative stress and inflammation and improved 
membrane repair [102]  
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Fig. 1. Nuclear erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signalling pathway and its downstream target effects. Under 
normal conditions, transcription factor Nrf2 is sequestered and degraded in the cytoplasm by its repressor Keap1 and proteosomal degradation, respectively. 
Activation of Nrf2 in response to stress signals such as reactive oxygen species (ROS) results in partial or complete dissociation of Nrf2 from Keap1. This allows 
dissociated or newly synthesised Nrf2 and its stabilizer protein DJ-1 to bypass Keap1, which is sequestered by p62, and translocate into the nucleus. Upon nuclear 
translocation, Nrf2 binds to the antioxidant response element (ARE) modulating the expression of an array of defensive genes including those that encode Phase II 
detoxifying enzymes such as superoxide dismutase (SOD), nicotinamide adenine dinucleotide phosphate quinone oxidoreductase 1 (NQO1), catalase (CAT) and heme 
oxygenase-1 (HO-1). This constitutes the endogenous antioxidant response. The activation of Nrf2 leads to broad downstream effects aside from detoxification and 
cellular defence against potentially harmful ROS, including calcium handling, mitohormesis (including biogenesis, maintenance and function), anti-inflammation 
(including suppression of pro-inflammatory cytokines), stem cell regeneration (i.e. satellite cell proliferation) and protein protection and homeostasis (namely, 
autophagy and heat shock protein expression). Nrf2 can amplify its own activation pathway by increasing p62 expression, which targets Keap1 and promotes 
degradation of the p62-Keap1 aggregate through autophagy. Created with BioRender.com 
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4.1. Targeting Ca2+-mediated pathology in DMD through Nrf2 
Although the primary deficiency of dystrophin instigates the path-
ogenesis of DMD, the pathophysiological events that render muscle fi-
bres more susceptible to necrosis are not fully understood. One proposed 
mechanism implicates abnormal intracellular Ca2+ homeostasis owing 
to disruption of sarcolemmal integrity and increased leak channel ac-
tivity, which over time leads to progressive fibre degeneration and 
skeletal muscle weakness [116]. While transient increases in intracel-
lular Ca2+ concentrations can induce beneficial muscle adaptations such 
as increased mitochondrial biogenesis [117] through hormesis, chroni-
cally increased intracellular Ca2+, which is evident in dystrophic muscle 
[118,119], can have detrimental effects on muscle function. Ca2+
accumulation impairs autophagy [120]; induces mitochondrial Ca2+
accumulation [121], permeability transition and apoptosis signalling 
[122]; and activates the protease, calpain, to degrade skeletal muscle 
architecture [122]. It has been proposed that Nrf2 can alter intracellular 
Ca2+. Nrf2 knockout (KO) mice present with impaired Ca2+ release and 
uptake kinetics in which the time-to-peak tension is halved. In these 
animals, the time-to-peak force and half-relaxation time are both 
doubled compared to Nrf2 positive mice [123]. This suggests that Nrf2 
facilitates Ca2+ handling as well as sarcoplasmic reticulum (SR) storage 
relative to the climatic Ca2+ concentration. An additional relevant 
finding involves the GPx8 protein, a GPx that is regulated by Nrf2124 and 
selectively modulates Ca2+ storage and fluxes [125]. Nrf2 silencing re-
sults in decreased GPx8 and dysregulated intracellular Ca2+ leading to 
cell death, whereas Nrf2 activation via DMF [124] and resveratrol [126] 
restores Ca2+ homeostasis [124] and enhances sarco/endoplasmic re-
ticulum Ca2+-ATPase (SERCA) activity [126] and re-uptake to facilitate 
muscle contraction. Since DMD is partly characterised by chronic 
Ca2+-induced skeletal muscle wasting, Nrf2 activation could effectively 
rescue functional impairments and convey therapeutic benefits for DMD 
patients. 
4.2. Targeting inflammation in DMD through Nrf2 
The redox-sensitive signalling Nrf2/Keap1 pathway (Fig. 1) plays a 
key role in the maintenance of cellular homeostasis under stress and 
inflammatory conditions. Nrf2 activation can attenuate inflammation 
via modulation of nuclear factor κ-light-chain-enhancer of activated B 
cells (NF-κB) [28,98,127–129], a family of transcription factors involved 
in inflammation, immune responsiveness and apoptosis [129]. NF-κB 
has been linked to hyperinflammatory diseases and is elevated in the 
skeletal muscles of DMD patients from infancy, driving inflammation 
and muscle degeneration [98,130]. Before clinical symptoms occur in 
DMD, strong activation of components of the innate immune system, 
including altered signalling via NF-κB, has been reported [82]. 
Increasing evidence links membrane instability with the release of 
cytoplasmic contents into the extracellular space [82,131], while the 
segmental degeneration and regeneration of myofibers [7,131] sustain 
this chronic activation of the innate immune system. In addition to 
individually affecting several signalling pathways for maintaining redox 
homeostasis, Nrf2 and NF-κB cross-talk to further amplify the levels of 
important redox modulators under basal and disease conditions [132]. 
Nrf2 also exerts its anti-inflammatory effect via the activation of HO- 
1 and its metabolism of heme [133,134]. HO-1 is at the core of 
Nrf2-mediated NF-κB inhibition and catalyses the degradation of heme 
into carbon monoxide (CO), free iron (Fe++) and biliverdin which is 
then converted to the antioxidant, bilirubin, by biliverdin reductase [30, 
130]. The role of HO-1 has not been extensively addressed in DMD 
however the ablation of HO-1 in the mdx mouse severely aggravates 
muscle damage and inflammation [135] whereas pharmacological in-
duction of HO-1 inhibits NF-κB and protects against muscle damage 
[136]. Nrf2 has been shown to bind in the vicinity of the IL-β and IL-18 
genes to decrease their transcription [137], thereby suggesting a direct 
inhibitory effect on nod-like receptor protein 3 (NLRP3) inflammasome 
priming. Mdx mice exposed to low doses of CO demonstrate reduced 
muscle damage and atrophy [136] based on HO-1 induction. Nrf2 
activation could possibly have a greater influence on the dystrophic 
phenotype as it not only induces HO-1, but also several other antioxidant 
enzymes. These data highlight that pharmacologically inducing Nrf2 can 
alleviate muscle inflammation in mdx mice via the inhibition of the 
NF-κB signalling pathway. Increased HO-1 activity also inhibits 
NF-κB-mediated transcription of pro-inflammatory cytokines and che-
mokines [137], matrix metalloproteinases [138], cell adhesion mole-
cules [139,140], and inflammatory enzymes such as cyclooxygenase-2 
[141,142] and inducible NOS (iNOS) [141,142]; most of which are 
overexpressed in dystrophic muscles [143–147]. Inflammation is a key 
component of the initiation and progression of diseases such as DMD, 
thus, activating the integrated signalling network involving Nrf2, NF-κB 
and HO-1 is a logical approach in DMD treatment. 
4.3. Targeting mitochondrial dysfunction in DMD through Nrf2 
Together with its cytoprotective activity against oxidants and other 
toxic stressors, increasing evidence supports the critical role of Nrf2 to 
maintain mitochondrial function [148]. Nrf2 is suggested to influence 
mitochondrial function via the modulation of substrate utilisation dur-
ing respiration [149]. Nrf2 KO mice present with elevated ROS pro-
duction, mitochondrial depolarisation, decreased ATP levels and 
impaired respiration and fatty acid oxidation [149–151], all of which 
can be rectified following Nrf2 activation [149] or KO of Keap1 [150]. 
Moreover, Hayashi et al. demonstrated that the canonical Nrf2 activator, 
DMF, increases mitochondrial DNA and mitochondrial complex mRNA 
expression in human fibroblasts and wild-type mice [152]. In the same 
study, DMF was also shown to rescue mitochondrial respiratory chain 
deficiency in fibroblasts of MS patients [152]. 
Mitochondrial integrity is also pivotal for mitochondrial function 
and cell survival. Mitophagy selectively removes excess or damaged 
mitochondria, maintaining integrity of the pool [93] via the 
PTEN-induced kinase 1 (PINK1)/Parkinson juvenile disease protein 2 
(Parkin) pathway. PINK1 accumulates on the outer membrane of the 
damaged mitochondria activating Parkin which functions as an E3 
ubiquitin ligase [153,154]. Parkin is recruited to the dysfunctional 
mitochondria, ubiquitinating outer mitochondrial membrane proteins 
to trigger selective autophagy via the multi-functional protein, p62 [93, 
153,154]. p62 expression is regulated in a Nrf2-dependant manner, 
forming a positive feedback loop to amplify its Nrf2-activator function 
[93]. In mdx mice, mitophagy is impaired due to defective PINK1/Parkin 
signalling [153,155]. Furthermore, Murata et al. demonstrated that 
stress-damaged mitochondria induce Nrf2-dependant transcription of 
the PINK1 gene [156], indicating that PINK1 expression is positively 
regulated by Nrf2. In regard to mitochondrial function, p62 plays a 
protective role by increasing the translocation of mitochondrial tran-
scription factor A (TFAM) [157], which is vital to mitochondrial DNA 
replication and transcription. In turn, deficiency of p62 exacerbates 
defects in mitochondrial membrane potential and energetics ultimately 
leading to mitochondrial dysfunction [157]. This is demonstrated by 
p62 KO mice that exhibit a rapid decline of mitochondrial function and 
present with an accelerated aging phenotype accompanied by severe 
oxidative stress [158]. It has also been proposed that coordinated in-
duction of HO-1 [159] and NQO1 [158] via activation of Nrf2 induces 
nuclear respiratory factor 1 (NRF1) expression to elicit the biogenesis of 
healthy mitochondria. Thus, Nrf2 affects crucial aspects of mitochon-
drial physiology as evidenced by the multitude of pathological and 
aging-related disorders associated with diminishing mitochondrial 
dysfunction and concomitant reduction in/suppression of Nrf2 signal-
ling [148,151,152,158]. Since we have established mitochondrial 
dysfunction as a driver of DMD [18,62], targeting this aspect through 
Nrf2 could be therapeutically beneficial for attenuating the disease. 
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4.4. Targeting proteostasis in DMD through Nrf2 
Complementing the regulation of antioxidant responsiveness, Nrf2 
also prepares the cell for toxic insult by amplifying protein quality 
control (PQC) measures. ROS, particularly, cause damage to proteins 
and prevent their proper assembly/reassembly and function, resulting in 
aggregation and protein conformational disease [160]. To combat this 
and maintain integrity of the proteome, Nrf2 induces molecular chap-
erones, the first line defence in proteostasis, to unfold misfolded pro-
teins. But for terminally misfolded and aggregated proteins, degradation 
and disposal are the only solutions – this occurs through either the 
calpain and ubiquitin proteasome systems (UPS) or through autophagy, 
respectively. In this manner, Nrf2 mitigates oxidative injury if ROS 
quenching cannot be achieved through endogenous antioxidant 
system-mediated hormesis [161]. 
Heat shock proteins (HSPs) are highly conserved molecular chap-
erone proteins that play a role in the assembly, aggregation, transport 
and folding of proteins [162]. They are induced by stressors including 
heat, oxidative stress, hypoxia and UV irradiation [163] and upregu-
lated by Nrf2 [164,165]. As well as chaperoning, it is suggested that 
several HSPs expressed in skeletal muscle play an essential role in 
muscle development and regeneration [166,167]. The most extensively 
studied HSP in skeletal muscle is HSP72, which protects and preserves 
SERCA expression and inhibits inflammatory mediators [163]. Phar-
macological (small molecule) HSP72 induction has demonstrated effi-
cacy against the gold standard mdx mouse model of DMD, as well as 
against the more severe dys-/utr- double KO mouse [168]. HSP72 in-
duction reduced creatine kinase (CK) levels – a clinical marker of muscle 
damage and disease progression – and improved the strength and 
function of mdx muscles [168], while in dys-/utr- mice, it reduced 
kyphosis, improved dystrophic muscle pathophysiology and extended 
lifespan [168]. The capacity for HSP inducers to modify disease pa-
thology highlights the strengths of this therapeutic avenue. We postulate 
that teamed with the other potentially disease modifying effects elicited 
by Nrf2, the therapeutic benefit of HSP induction through Nrf2 activa-
tion could be amplified further. 
Akin to molecular chaperoning, Nrf2 activation governs autophagy- 
mediated protein and organelle maintenance and proteasomal capacity 
[169]. In mouse models, autophagy deficiency induces metabolic 
impairment and accumulation of abnormal organelles, lipids and 
autophagy-specific substrates such as p62 [170]. Excessive p62 protein 
accumulation is cytotoxic, escalating both inflammation and oxidative 
stress [171]. A non-canonical mechanism of Nrf2 activation induced by 
autophagy deregulation has recently been described [171], differing 
from the previously described canonical pathway [105]. Accumulated 
p62 binds to Keap1 hindering its inhibitory effect on Nrf2 [171], which 
results in the activation of Nrf2 target genes. Autophagy maintains the 
integrity of the Nrf2/Keap1 pathway by governing Keap1 turnover. In 
DMD, autophagy is severely impaired in both human patients [172,173] 
and mdx mice [172–174] shown by reduced expression of light chain 
3-II (LC3-II) [70,173] and p62 aggregation [29], indicative of the 
accumulation of damaged protein aggregates owing to reduced auto-
phagic flux [173]. Importantly, the PQC system in mdx muscles remains 
amenable to therapeutic intervention [175]. However, whether auto-
phagy can be targeted through Nrf2 activation as a therapeutic inter-
vention for DMD remains to be investigated. 
The proteasome is implicated in the removal of normal and 
abnormal, denatured or otherwise damaged proteins [169]. Adaptation 
to oxidative stress involves increased expression of the 20S proteasome 
[176], and, both insufficient proteolytic capacity or increased oxidant 
production can result in compromised cellular function [169]. 
Supressing Nrf2 induction significantly limits the adaptive increases in 
cellular proteolytic capacity including the 20S proteasome [169]. In 
contrast, Nrf2 inducers largely increase 20S proteasome expression and 
cellular resistance to oxidative stress [169], suggesting adaptation is 
dependent on Nrf2 upregulation and its nuclear translocation. The UPS 
system is notoriously upregulated in dystrophin-deficient muscle and 
suppression of proteasomal activity has been pursued to mitigate muscle 
wasting [177]. This strategy is clearly in conjecture with Nrf2-mediated 
proteasomal amplification. However, despite successful treatment of in 
vivo animal [177–179] and ex vivo human models [177] of DMD with 
UPS inhibitor drugs, long term human treatment is associated with 
notable side effects and toxicity [180]. These conflicting data highlight 
the importance of an active proteasomal system in muscle maintenance, 
particularly in disease states, as well as the complexity of the pathways 
that regulate it. Recent data has shed light on this story. NF-κB driven 
stress signalling appears to orchestrate re-routing of mis-/un-folded 
protein aggregates into autophagy in favour of the 26S proteasome 
[181]. Re-establishing normal proteasomal/autophagic balance, rather 
than inhibiting the UPS, thus might prove a better therapeutic strategy 
against DMD and could be achieved through Nrf2 activation. 
4.5. Targeting tissue repair and regeneration in DMD through Nrf2 
In addition to cellular protection, Nrf2 is an important regulator of 
tissue repair and regeneration [182]. Skeletal muscles harbour a popu-
lation of “satellite” stem cells (SCs) which through induction of the 
myogenic program factors, MyoD and myogenin [25,183], undergo 
proliferation, differentiation, fusion and maturation to facilitate muscle 
repair. Nrf2 plays an important role in muscle regeneration as it pro-
longs SC proliferation via the upregulation of MyoD, and suppresses SC 
differentiation by downregulating myogenin [184]. Nrf2 ablation re-
duces MyoD mRNA and protein expression, delaying muscle regenera-
tion following injury [185]. Signal transducer and activator of 
transcription 3 (STAT3) regulates SC fate choices during regeneration by 
promoting SC progression into committed myogenic progenitors and 
drives differentiation [186]. In conjunction with STAT3, Metabolism 
Regulating Signalling Molecule A (Fam3a) acts downstream to regulate 
SC myogenic lineage progression and development of skeletal muscle in 
vivo [183]. Nrf2 stimulates SC proliferation and differentiation by 
inducing STAT3-mediated secretion of Fam3a to switch the metabolic 
phenotype of SCs in favour of mitochondrial oxidative phosphorylation 
and their commitment to myogenic lineage [183]. In dystrophic muscle, 
loss of STAT3 leads to dysregulation of numerous genes, depletion of SCs 
as well as heightened inflammation and fibrosis [187]. Transient re-
ceptor potential, subfamily A1 (TRPA1) channel activation has also been 
shown to enhance vital aspects of skeletal muscle repair including pro-
motion of myoblast migration, fusion and potentially SC activation 
[188] through Ca2+-dependent events. Potent Nrf2 activator, DMF, has 
been shown to directly activate TRPA1 in immune cell populations 
[189], however it is unknown whether this effect extends to skeletal 
muscle. Indeed, studies have revealed that injection of freshly isolated 
SC subsets into dystrophin deficient mdx mice renew the endogenous 
stem cell pool and contribute to improving efficiency of subsequent 
injury repair [190–192]. This demonstrates that therapies which 
enhance muscle stem cell activity provide an attractive therapeutic 
avenue for DMD – pharmacological therapeutics perhaps even more so 
since muscle stem cell transplant therapy is difficult to administer to the 
entire skeletal muscle mass for systemic benefit. 
5. The case for therapeutic pharmacological Nrf2 activation 
against skeletal muscle wasting 
Nrf2 as an exploitable drug target to treat chronic disease is an 
emerging area of research [152,193–199] since it is capable of inducing 
an array of downstream target effectors relevant to the pathogenesis of 
many chronic disease states. There are numerous pharmaceutical and 
nutraceutical activators of Nrf2 with only a few approved as disease 
modifying treatment of MS: DMF [200,201], MMF and DRF; schistoso-
miasis: oltipraz; and primary biliary cirrhosis: ursodiol. Several other 
molecules are in various stages of development for the treatment of 
progressive degenerative diseases with neurological and skeletal 
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muscular symptomology (summarised in Table 2) including Alzheimer’s 
Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Rheu-
matoid Arthritis and Diabetic Nephropathy. 
While there are currently no clinical trials investigating Nrf2 acti-
vators against skeletal muscle wasting, or specifically, for therapeutic 
intervention in neuromuscular disease, there is a growing data set which 
demonstrates that targeting Nrf2 could be beneficial. One of the most 
debilitating age-associated alterations is the progressive loss of fat-free 
skeletal muscle mass, a phenomenon commonly known as sarcopenia 
[210]. Eventual loss of muscle mass and strength, in conjunction with 
increased adiposity, may occur because of metabolic changes related to 
a natural age-related decline in physical and biological properties as 
well as a sedentary lifestyle. Sedentariness can reduce resistance to 
stressors such as ROS [210], and is a feature of progressed DMD when 
the magnitude of muscle mass and functional loss leaves sufferers 
disabled [6], thus perpetuating sedentary atrophy. Overexpression of 
antioxidant genes such as CAT in model organisms were able to modify 
oxidative stress tolerance and extend lifespan by up to 50% [211,212]. 
Therefore, signalling pathways such as the Nrf2-ARE pathway that 
regulate the antioxidant response could be plausible modifiers of the 
aging process. 
Distinct similarities between Nrf2 KO mice and aged mice are 
evident. Both exhibit intense sensitivity to various acute and chronic 
stressors [213], suggesting that disruptions in Nrf2/Keap1 redox sig-
nalling may occur throughout the aging process. Safdar et al. investi-
gated the role of the Nrf2/Keap1 signalling pathway in aged skeletal 
muscle (50–75 years old) of healthy individuals and the modulatory 
capacity of an active lifestyle on the Nrf2 response [214]. Active elderly 
subjects showed increased total Nrf2 content, decreased Keap1 protein 
and activation of Phase II enzymes indicating that the Nrf2-ARE 
pathway is still capable of hormetic adaptations in response to 
increased oxidative stress. In contrast, sedentary elderly subjects 
exhibited decreased Nrf2 function and increased lipid peroxidation 
suggesting dysfunctional Nrf2/Keap1 signalling. Similar findings are 
observed in aged Nrf2 KO mice (>24 months) with increased ROS 
production, ubiquitination, apoptosis and oxidative damage evident in 
skeletal muscle [196]. Another study concluded that nuclear import of 
Nrf2 is impaired in older adults (>63 years) compared to young adults 
and that gene expression of downstream antioxidant targets and Nrf2 is 
repressed [215]. These studies highlight the importance of the 
Nrf2/Keap1 signalling pathway in maintaining the cellular redox state 
in elderly/aged skeletal muscle, but perhaps most profoundly, that 
pharmacological Nrf2 activation should be considered in 
sub-populations of individuals who cannot voluntarily exercise due to 
disease and disability to protect skeletal muscle mass. 
Akin to sarcopenia, Nrf2 expression in DMD patients declines as the 
disease progresses [70] suggesting that the endogenous Nrf2-mediated 
cytoprotective response declines too. In infants (0–2 year old) and 
young (2–9 year old) DMD boys, Nrf2 protein expression and activation 
declines with age/weight-bearing activity/disease progression, as does 
downstream Phase II enzyme expression [70]. In the skeletal muscle of 
infant DMD patients in particular, gene expression of Nrf2 and Phase II 
enzyme expression (i.e. NQO1 and SOD) is notably higher than in 
healthy age-matched controls but paradoxically, HO-1 is downregulated 
[70]. These data suggest oxidative stress in skeletal muscle early in the 
disease but subnormal Nrf2-dependent anti-inflammation signalling 
through HO-1. This study defines the critical role of oxidative stress on 
muscle wasting, particularly concerning the early pathogenic mecha-
nisms underlying DMD. It also begs the question whether Nrf2 can 
induce hormetic adaptations in the dystrophic environment necessary to 
elicit a therapeutic response through pharmacological activation? 
To answer this, our group recently investigated the therapeutic 
benefits of Nrf2 activation in the mdx mouse following 8-week treatment 
with the fumarate-generating metabolite, adenylosuccinic acid (ASA) 
[19]. ASA is a product of the Purine Nucleotide Cycle (PNC), which is 
activated during times of stress to drive the recovery of ATP from inosine 
monophosphate (IMP) [216]. The enzymatic cleavage of ASA also yields 
fumarate that is transported into the mitochondria (via the 
Table 2 
Summary of Nrf2 activators that are either approved for human use or have been, or are currently being, examined via human/animal trials.   
Compound Disease Phase of Trial Trial Identifier 
Approved for Human 
Use 
Dimethyl Fumarate Multiple Sclerosis Approved N/A 
Psoriasis Approved 
Diroximel Fumarate Multiple Sclerosis Approved 
Monomethyl Fumarate Multiple Sclerosis Approved 
Oltipraz Schistosomiasis Approved 
Ursodiol Primary Biliary Cirrhosis Approved 
Current Human Trials Bardoxolone Methyl Chronic Kidney Disease/Type II Diabetes Phase III 
[202] 
NCT01351675 
Curcumin Alzheimer’s Disease Phase II NCT00099710 
Asthma Phase II NCT04353310 
Diacetylbis(N(4)-methylthiosemicarbazonato Copper (II) 
(CuATSM) 
Amyotrophic Lateral Sclerosis/Motor Neuron 
Disease 
Phase III NCT04082832 
Rectal Cancer Phase II NCT03951337 
Dimethyl Fumarate Cutaneous T Cell Lymphoma Phase II NCT02546440 
Glioblastoma Multiforme Phase I NCT02337426 
Rheumatoid Arthritis Phase II NCT00810836 
Omaveloxolone (RTA 408) Friedreich’s Ataxia Phase II NCT02255435 
Melanoma Phase II NCT02259231 
Mitochondrial Myopathy Phase II NCT02255422 
Resveratrol Alzheimer’s Disease Phase II [203] NCT01504854 
Endometriosis Phase IV 
[204] 
NCT02475564 
Huntington Disease Phase III NCT02336633 
Type II Diabetes Phase I NCT01677611 
Sulforaphane Autism Spectrum Disorder Phase III NCT02654743 
Chronic Obstructive Pulmonary Disease Phase II [205] NCT01335971 
Schizophrenia Phase II NCT02810964 
Animal Trials Monomethyl Fumarate Sickle Retinopathy [206]  
Resveratrol Progressive Renal Injury [207] 
Sulforaphane Duchenne Muscular Dystrophy [97–99] 
Breast Cancer [208] 
Prostate Cancer [209]  
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malate-aspartate shuttle), expanding the tricarboxylic acid cycle and 
specifically driving the malate > fumarate > succinate flux through 
Complex II to augment ATP production [216]. Treatment with ASA 
improved mitochondrial viability, reduced lipid and connective tissue 
infiltration, and significantly improved histopathological features of 
murine DMD. Originally, it was thought that ASA exerted it effects 
metabolically but we have since identified that ASA upregulates Nrf2 
protein expression (Rybalka et al., Manuscript in review [217]). In 
immortalised human DMD cells, ASA has antioxidant effects through 
reduction of mitochondrial superoxide [19]. Our data is consistent with 
Sun et al. who treated dystrophic mice with the canonical Nrf2 inducer, 
sulforaphane (SFN) [97–99], which mediates its effects through induc-
tion of NQO1 [218] and HO-1 [193]. These studies demonstrated that 
SFN treatment of the mdx mouse induced NQO1 and HO-1 expression, 
increased skeletal muscle mass and force production, decreased NF-κB 
[98] and the inflammatory cytokine TNF-α [99], and improved sarco-
lemmal integrity as evidenced by a decrease in Evans Blue Dye perme-
ation [97]. SFN also reduced fibrosis through inhibition of TGFβ/Smad 
signalling [99]. Thus, Nrf2 activators appear useful to ablate the central 
mechanistic hallmarks of dystrophic progression. 
As yet, there are no trials in DMD patients investigating established 
Nrf2 activator drugs against the disease course. However, in a 2019 case 
study, treatment with ASEA Redox Supplement®, a deionised saline 
water with Nrf2 activator capacity, was shown to attenuate serum bio-
markers of DMD progression (CK, CK-MB (cardiac muscle-specific) and 
magnesium levels) in one young DMD patient. Treatment occurred over 
16 months with escalating dosage (4–7 mL/kg/day [219]) and impor-
tantly demonstrated no liver toxicity, a side-effect of perpetual genetic 
Nrf2 induction. While the data generated from the case study are 
promising, it is important to highlight that the Nrf2 activator supple-
ment was administered in combination with L-carnitine, omega-3 fatty 
acids and a vitamin cocktail which could significantly confound inter-
pretation of the data. 
6. Balancing the argument: Could too much Nrf2 be 
detrimental? 
Whilst Nrf2 is undoubtedly a strong molecular cytoprotectant, it is 
important to consider several factors when proposing its chronic in-
duction to treat disease: (1) repressor molecules like Keap1 have been 
evolutionary conserved to maintain low Nrf2 levels during the basal 
redox steady state; (2) chronic unsolicited Nrf2 overactivation may tip 
redox imbalance in the opposite direction by driving reductive stress and 
pathogenesis; and (3) other non-transcriptional activities relating to 
Nrf2’s sequestration of Keap1 are important for tissue growth, repair 
and maintenance (e.g. angiogenesis). 
Genetic overexpression/overactivation models have provided 
insight regarding the negative effects of unsolicited Nrf2 activation. In 
Drosophila, high Nrf2 levels cause developmental lethality, or after 
inducible activation, altered mitochondrial bioenergetics, diabetes onset 
and accelerated aging through modulating insulin/IGF signalling to 
induce a stress tolerance phenotype over a growth and longevity 
phenotype [220]. In mice, persistent Nrf2 overactivation reduces life-
span through driving stem cell exhaustion [221], causes hepatomegaly, 
glycogenosis and steatosis [222], and drives cardiomyopathy and heart 
failure when autophagy is impaired [223]. While these data provide 
important proof of concept evidence that Nrf2 overactivation can be 
lethal, it is important to highlight that genetic overexpression/activation 
and pharmacological activation represent two very different therapeutic 
approaches. Where pharmacological activators work through support-
ing hormesis proportionate to the dose administered, the magnitude and 
persistence of genetic activation overrides hormesis and the adaptive 
response to environmental stress cues. Indeed, mild genetic Nrf2 over-
activation of Drosophila induced cytoprotection, enhanced stress toler-
ance and extended lifespan, suggesting that functional hormesis is 
required to elicit beneficial effects and can be achieved through 
modifying the degree of Nrf2 activation. 
Without doubt, the most controversial outcome of prolonged and 
gain-of-function Nrf2 activation concerns cancer progression 
[224–226]. It is well established that cytoprotection elicited through 
Nrf2 activation is important for the suppression of carcinogenesis in the 
first instance [227–230]. However, Nrf2 activity in aggressively malig-
nant cells promotes tumorigenesis and metastasis [228,231–233], in-
creases resistance to platinum-based chemotherapy [224,234–237] and 
has been associated with overall poorer prognosis [238]. These studies 
suggest a protective role of Nrf2 in the early stages of cancer compared 
to a more advanced stage where Nrf2 overexpression assists cancer cells 
to adapt to tumorigenic demands. Although there is considerable evi-
dence suggesting that Nrf2 activation is both safe to use and effective 
against several other diseases, it is essential to further investigate 
whether chronic, long-term Nrf2 activation therapy increases the risk of 
cancer development. 
Nrf2 activation may also be detrimental by causing reductive stress. 
There is surmounting evidence that reductive stress, as much as oxida-
tive stress, can promote pathogenesis through abolishing functional ROS 
signalling and/or increasing reducing equivalents [239,240]. Oxidative 
modification of cysteines, for example, is essential for controlling pro-
tein synthesis and quality control in the endoplasmic reticulum and for 
the activation of growth factor-mediated protein kinase signalling. 
Similarly, ROS are essential for the responsive metabolic reprogram-
ming and angiogenesis evoked by hypoxia through HIF1α. Paradoxi-
cally, reductive stress appears to eventually propagate oxidative stress 
through the consumption of reducing equivalents by mitochondria and 
other ROS producing enzymes in a mechanism that is not entirely clear 
[239]. This may explain how ROS scavenging antioxidants administered 
at certain (generally high) concentrations can activate Nrf2 through 
pro-oxidant activity. In the context of drug targeting for the treatment of 
DMD, it would be necessary to balance the anti-oxidant/pro-reducing 
equivalent/pro-oxidant activity elicited by the chosen Nrf2 activator 
drug through dosage and regimen refinement to ensure efficacy. The 
successful use of Nrf2 activator drugs against other diseases (e.g. MS) 
characterised by chronic and excessive oxidative stress and inflamma-
tion highlights that this can be achieved in the clinic [241]. 
Finally, it has recently emerged that Nrf2 elicits other crucial cellular 
functions independent of its transcriptional activity, which could be 
abolished by chronic unsolicited Nrf2 activation. Through biologically 
anchoring Keap1, Nrf2 drives angiogenesis by endothelial cells, and 
therefore, maintains tissue oxygenation [242]. This is fundamentally 
important in DMD, because dystrophin is also expressed in vascular 
endothelial and smooth muscle cells and without it, angiogenesis and 
muscle oxygenation is already impaired (reviewed in Ref. [243]). In this 
regard, it would be important to consider the consequence of Nrf2 
activation (i.e. dissociation) on Keap1. For example, p62 has been shown 
to aggregate with Keap1 which might retain Keap1’s pro-angiogenic 
regulatory function independent of Nrf2 but only at a rate consistent 
with the rate of autophagy activity [244]. This aspect requires further 
investigation. 
7. Conclusion 
The Nrf2 signalling pathway governs the antioxidant, metabolic and 
mitochondrial re-programming response to cellular stress and is the 
target of numerous established and investigational new drugs to treat 
chronic disease. Pharmacological Nrf2 activators have the potential to 
therapeutically exploit key targets involved in the pathogenic regulation 
of diseases such as DMD, which include Ca2+ dysregulation, mitochon-
drial dysfunction, compromised antioxidant responsivity, inflammation 
and impaired satellite cell-mediated regenerative activity. There is 
developing pre-clinical evidence in this regard, using established and 
novel Nrf2 activator compounds which show capacity to attenuate 
murine (mdx) MD. Since we provide here, only a theoretial context for 
Nrf2-mediated therapy against DMD, further translational investigations 
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on the therapeutic effects and safety of novel, as well as repurposed, 
modulators of the Nrf2 signalling pathway should be undertaken in 
clinical trials. Given the success of long-term pharmacological Nrf2 
therapy against MS in particular, as well as an isolated case study using 
an Nrf2 activator supplement in one DMD patient which demonstrated 
promising effects on disease biomarkers, Nrf2 could be a useful thera-
peutic target against not only DMD, but also other neuromuscular, 
neurodegenerative and metabolic diseases. 
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[10] S. Mata López, C. Balog-Alvarez, S. Vitha, A.K. Bettis, E.H. Canessa, J. 
N. Kornegay, P.P. Nghiem, Challenges associated with homologous directed 
repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine 
Duchenne muscular dystrophy, PLoS One 15 (2020), e0228072. 
[11] S. Cirak, V. Arechavala-Gomeza, M. Guglieri, L. Feng, S. Torelli, K. Anthony, 
S. Abbs, M.E. Garralda, J. Bourke, D.J. Wells, G. Dickson, M.J.A. Wood, S. 
D. Wilton, V. Straub, R. Kole, S.B. Shrewsbury, C. Sewry, J.E. Morgan, K. Bushby, 
F. Muntoni, Exon skipping and dystrophin restoration in patients with Duchenne 
muscular dystrophy after systemic phosphorodiamidate morpholino oligomer 
treatment: an open-label, phase 2, dose-escalation study, Lancet 378 (2011) 
595–605. 
[12] M. Kinali, V. Arechavala-Gomeza, L. Feng, S. Cirak, D. Hunt, C. Adkin, 
M. Guglieri, E. Ashton, S. Abbs, P. Nihoyannopoulos, M.E. Garralda, 
M. Rutherford, C. McCulley, L. Popplewell, I.R. Graham, G. Dickson, M.J. 
A. Wood, D.J. Wells, S.D. Wilton, R. Kole, V. Straub, K. Bushby, C. Sewry, J. 
E. Morgan, F. Muntoni, Local restoration of dystrophin expression with the 
morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, 
placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol. 8 
(2009) 918–928. 
[13] J.C. van Deutekom, A.A. Janson, I.B. Ginjaar, W.S. Frankhuizen, A. Aartsma-Rus, 
M. Bremmer-Bout, J.T. den Dunnen, K. Koop, A.J. van der Kooi, N.M. Goemans, S. 
J. de Kimpe, P.F. Ekhart, E.H. Venneker, G.J. Platenburg, J.J. Verschuuren, G. 
J. van Ommen, Local dystrophin restoration with antisense oligonucleotide 
PRO051, N. Engl. J. Med. 357 (2007) 2677–2686. 
[14] A. Hayes, D.A. Williams, Contractile function and low-intensity exercise effects of 
old dystrophic (mdx) mice, Am. J. Physiol. Cell Physiol. 274 (1998) 
C1138–C1144. 
[15] A. Hayes, D.A. Williams, Beneficial effects of voluntary wheel running on the 
properties of dystrophic mouse muscle, J. Appl. Physiol. 80 (1996) 670–679. 
[16] A.J. Cheng, D.C. Andersson, J.T. Lanner, Can’t live with or without it: calcium 
and its role in Duchenne muscular dystrophy-induced muscle weakness. Focus on 
“SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse 
models”, Am. J. Physiol. Cell Physiol. 308 (2015) C697–C698. 
[17] M.C. Hughes, S.V. Ramos, P.C. Turnbull, I.A. Rebalka, A. Cao, C.M.F. Monaco, N. 
E. Varah, B.A. Edgett, J.S. Huber, P. Tadi, L.J. Delfinis, U. Schlattner, J. 
A. Simpson, T.J. Hawke, C.G.R. Perry, Early myopathy in Duchenne muscular 
dystrophy is associated with elevated mitochondrial H2O2 emission during 
impaired oxidative phosphorylation, J Cachexia Sarcopenia Muscle 10 (2019) 
643–661. 
[18] C.A. Timpani, A. Hayes, E. Rybalka, Revisiting the dystrophin-ATP connection: 
how half a century of research still implicates mitochondrial dysfunction in 
Duchenne Muscular Dystrophy aetiology, Med. Hypotheses 85 (2015) 
1021–1033. 
[19] C.A. Timpani, C.A. Goodman, C.G. Stathis, J.D. White, K. Mamchaoui, G. Butler- 
Browne, N. Gueven, A. Hayes, E. Rybalka, Adenylosuccinic acid therapy 
ameliorates murine Duchenne Muscular Dystrophy, Sci. Rep. 10 (2020) 1125. 
[20] L. Austin, M. de Niese, A. McGregor, H. Arthur, A. Gurusinghe, M.K. Gould, 
Potential oxyradical damage and energy status in individual muscle fibres from 
degenerating muscle diseases, Neuromuscul. Disord. 2 (1992) 27–33. 
[21] K.G. Woodman, C.A. Coles, S.R. Lamandé, J.D. White, Nutraceuticals and their 
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